<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189589</url>
  </required_header>
  <id_info>
    <org_study_id>207674</org_study_id>
    <secondary_id>2017-001073-16</secondary_id>
    <nct_id>NCT03189589</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Dose of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2269557 is being developed as an anti-inflammatory and anti-infective agent for the
      treatment of inflammatory airways diseases. This is the first study using a new formulation
      of GSK2269557 in healthy subjects and will evaluate the safety, tolerability and PK of a
      single dose of GSK2269557. Data derived from this study will inform on the PK profile and
      systemic exposure expected during Phase 2b. Approximately twelve healthy subjects will be
      randomized to receive a single dose of GSK2269557 750 micrograms (µg) or a single dose of
      GSK2269557 500 µg via the ELLIPTA® dry powder inhaler (DPI) formulated in a blend containing
      0.4 percent magnesium stearate (MgSt) in 1:1 ratio. This randomized, parallel group study
      will be carried out in 3 phases, including screening phase, treatment phase and follow-up
      phase. The total study duration for each subject will be up to 6 weeks. ELLIPTA is a
      registered trademark of GlaxoSmithKline group of companies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">July 24, 2017</completion_date>
  <primary_completion_date type="Actual">July 24, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy subjects will be randomized to receive GSK2269557 750 µg or GSK2269557 500 µg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind study and subjects and investigator will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean GSK2269557 Plasma Concentration</measure>
    <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
    <description>Whole blood samples of approximately 2 milliliters were collected for measurement of plasma concentrations of GSK2269557 at the indicated time points. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic (PK) Population which comprised of all randomized participants in the Safety Population and for whom a PK sample was obtained and analyzed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2269557</measure>
    <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
    <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Drug Concentration (Cmax) and Concentration at Trough (Ctrough) of GSK2269557</measure>
    <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
    <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Drug Concentration (Tmax) and Terminal Half-life (t1/2)</measure>
    <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
    <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Vital Signs of Potential Clinical Importance</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Vital signs included blood pressure (systolic and diastolic blood pressure) and heart rate measurements and were assessed with the participant in a semi-supine position after 5 minutes rest. The potential clinical concern range values for vital signs were: systolic blood pressure (lower &lt;85 millimeters of mercury and higher &gt;160 millimeters of mercury), diastolic blood pressure (lower &lt;45 millimeters of mercury and higher &gt;100 millimeters of mercury) and heart rate (lower &lt;40 beats per minute and higher &gt;110 beats per minute). Number of participants with vital signs of potential clinical importance are presented. Safety Population comprised of all randomized participants who received at least one dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Twelve-lead ECG was obtained using an ECG machine which automatically measured PR, QRS, QT and corrected QT (QTc) intervals. ECG parameters and their potential clinical importance range values were: absolute QTc interval (lower &gt;450 milliseconds [msec]), absolute PR interval (lower &lt;110 msec and upper &gt;220 msec), absolute QRS interval (lower &lt;75 msec and upper &gt;110 msec). Number of participants with electrocardiogram (ECG) values of potential clinical importance are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Baseline and Day 1</time_frame>
    <description>The maximal amount of air forcefully exhaled in 1 second (FEV1) and forced vital capacity (FVC) was measured using a spirometer. Baseline was latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline values from post-dose visit values. Mean change from Baseline in FVC and FEV1 is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Abnormalities of Potential Clinical Importance</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Hematology parameters and their potential clinical concern values were: Hematocrit (high flag: &gt;0.54 and change from Baseline: decrease of 0.075), hemoglobin (high flag: &gt;180 grams per Liter and change from Baseline: decrease of 25 grams per Liter), lymphocytes (low flag: &lt;0.8*10^9 cells per Liter), neutrophil count (low flag: &lt;1.5*10^9 cells per Liter), platelet count (low flag: &lt;100*10^9 cells per Liter and high flag: &gt;550*10^9 cells per Liter) and white blood cell count (low flag: &lt;3*10^9 cells per Liter and high flag: &gt;20*10^9 cells per Liter). Number of participants with hematology abnormalities of potential clinical importance are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Clinical chemistry parameters and their potential clinical concern range values were: calcium (low flag &lt;2 millimoles/Liter [mmol/L] and high flag &gt;2.75 mmol/L), creatinine (high flag &gt;44.2 micromoles/Liter increase in change from Baseline), glucose (fasting) (&lt;3 mmol/L and &gt;9 mmol/L), potassium (low flag &lt;3 mmol/L and high flag &gt;5.5 mmol/L above ULN), sodium (low flag &lt;130 mmol/L and high flag &gt;150 mmol/L). Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>Up to 12 days post-dose</time_frame>
    <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GSK2269557 500 µg receivers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized healthy subjects will receive single dose of GSK2269557 500 µg via inhalation route via the ELLIPTA DPI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2269557 750 µg receivers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized healthy subjects will receive single dose of GSK2269557 750 µg via inhalation route via the ELLIPTA DPI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 500 µg</intervention_name>
    <description>GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.</description>
    <arm_group_label>GSK2269557 500 µg receivers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2269557 750 µg</intervention_name>
    <description>GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.</description>
    <arm_group_label>GSK2269557 750 µg receivers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 to 75 years of age inclusive, at the time of signing the informed
             consent.

          -  Subjects who are overtly healthy as determined by medical evaluation including medical
             history, physical examination, laboratory tests, and ECG tests. Re-screening will be
             allowed once, at the discretion of the Principal Investigator in consultation with
             GlaxoSmithKline (GSK) medical monitor.

          -  Normal spirometry at Screening FEV1 and FVC &gt;=80 percent of predicted (measurements to
             be taken in triplicate and the highest value for each component must be &gt;=80 percent
             of predicted).

          -  Body weight &gt;=50 kilograms (kg) and body mass index (BMI) within the range 18.0 - 35.0
             kg per square meter (kg/m^2) (inclusive).

          -  Male or female: A male subject must agree to use contraception during the treatment
             period for at least 5 half-lives plus 90 days after the last dose of study treatment
             and refrain from donating sperm during this period. A female subject is eligible to
             participate if she is not pregnant, not breastfeeding, and at least one of the
             following conditions applies: Not a woman of childbearing potential (WOCBP) or A WOCBP
             who agrees to follow the contraceptive guidance during the treatment period for at
             least 5 half-lives plus 90 days after the last dose of study treatment.

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  Asthma or a history of asthma (except in childhood, which has now remitted).

          -  Significant history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs;
             constituting a risk when taking the study treatment; or interfering with the
             interpretation of data.

          -  Abnormal blood pressure [as determined by the investigator].

          -  Alanine transaminase (ALT) &gt;1.5 times upper limit of normal (ULN).

          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin
             is fractionated and direct bilirubin &lt;35 percent).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  QTc interval &gt;450 milliseconds (msec).

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications within 7 days prior to dosing.

          -  Live vaccine(s) within 1 month prior to screening, or plans to receive such vaccines
             during the study.

          -  Participation in the study would result in loss of blood or blood products in excess
             of 500 milliliters (mL) within 56 days.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day. Consider adding the following criteria if subjects can only be enrolled
             once per study.

          -  Current enrollment or past participation within the last 90 days before signing of
             consent in any other clinical study involving an investigational study treatment or
             any other type of medical research

          -  Presence of Hepatitis B surface antigen (HBsAg) at screening Positive Hepatitis C
             antibody test result at screening. Subjects with positive Hepatitis C antibody due to
             prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C
             Ribonucleic Acid (RNA) test is obtained.

          -  Positive Hepatitis C RNA test result at screening or within 3 months prior to first
             dose of study treatment.

          -  Positive pre-study drug/alcohol screen.

          -  Positive human immunodeficiency virus (HIV) antibody test.

          -  Regular use of known drugs of abuse.

          -  Regular alcohol consumption within 3 months prior to the study defined as: An average
             weekly intake of &gt;14 units for males and females. One unit is equivalent to 8 grams
             (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine
             or 1 (25 mL) measure of spirits.

          -  Current smoker or a history of smoking within 6 months of Screening, or a total pack
             year history of &gt;5 pack years. [Number of pack years = (number of cigarettes per
             day/20) multiplied by number of years smoked]

          -  Sensitivity to any of the study treatments, or components thereof (including lactose
             and MgSt), or drug or other allergy that, in the opinion of the investigator or
             medical monitor, contraindicates participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0GG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Wilson R, Templeton A, Leemereise C, Eames R, Banham-Hall E, Hessel EM, Cahn A. Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals. Clin Ther. 2019 Jun;41(6):1214-1220. doi: 10.1016/j.clinthera.2019.04.008. Epub 2019 May 7.</citation>
    <PMID>31076203</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <results_first_submitted>July 6, 2018</results_first_submitted>
  <results_first_submitted_qc>July 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 14, 2019</results_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy</keyword>
  <keyword>ELLIPTA</keyword>
  <keyword>Safety</keyword>
  <keyword>GSK2269557</keyword>
  <keyword>Inhalation</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/SearchAllPostings.aspx?searchparam=207674</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 4, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03189589/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT03189589/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at a single center in the United Kingdom from 15-June-2017 to 24-July-2017.</recruitment_details>
      <pre_assignment_details>A total of 19 participants were screened for this study, of which 7 participants were screen failures and 12 participants were randomized to treatment. The reasons for screen failure were: did not meet inclusion/exclusion criteria (6 participants) and withdrawal by participant (1 participant).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2269557 500 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 500 micrograms (mcg) via the ELLIPTA dry powder inhaler (DPI) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>GSK2269557 750 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2269557 500 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>GSK2269557 750 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="6.21"/>
                    <measurement group_id="B2" value="42.7" spread="10.98"/>
                    <measurement group_id="B3" value="48.3" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean GSK2269557 Plasma Concentration</title>
        <description>Whole blood samples of approximately 2 milliliters were collected for measurement of plasma concentrations of GSK2269557 at the indicated time points. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic (PK) Population which comprised of all randomized participants in the Safety Population and for whom a PK sample was obtained and analyzed.</description>
        <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean GSK2269557 Plasma Concentration</title>
          <description>Whole blood samples of approximately 2 milliliters were collected for measurement of plasma concentrations of GSK2269557 at the indicated time points. The pharmacokinetic parameters were calculated by standard non-compartmental analysis. Pharmacokinetic (PK) Population which comprised of all randomized participants in the Safety Population and for whom a PK sample was obtained and analyzed.</description>
          <population>PK Population.</population>
          <units>Picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2175.5" spread="843.68"/>
                    <measurement group_id="O2" value="1871.8" spread="985.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 minutes post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="480.7" spread="155.28"/>
                    <measurement group_id="O2" value="530.7" spread="260.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.9" spread="83.85"/>
                    <measurement group_id="O2" value="414.6" spread="187.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259.7" spread="81.60"/>
                    <measurement group_id="O2" value="424.0" spread="186.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.5" spread="52.94"/>
                    <measurement group_id="O2" value="319.5" spread="109.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" spread="48.71"/>
                    <measurement group_id="O2" value="248.9" spread="71.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.0" spread="38.31"/>
                    <measurement group_id="O2" value="145.2" spread="40.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>120 hours post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="19.30"/>
                    <measurement group_id="O2" value="40.1" spread="26.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2269557</title>
        <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Drug Concentration Versus Time Curve (AUC) From Zero to Time t (AUC [0 to t]), AUC From Zero to 24 Hours (AUC [0 to 24]) and AUC From Zero to Infinity (AUC [0 to Inf]) of GSK2269557</title>
          <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Hours*picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0 to t), n=6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14032.8" spread="5027.09"/>
                    <measurement group_id="O2" value="18468.7" spread="7007.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to 24), n=6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6000.6" spread="1646.07"/>
                    <measurement group_id="O2" value="8497.7" spread="3189.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0 to inf), n=4,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19291.7" spread="3788.10"/>
                    <measurement group_id="O2" value="23340.9" spread="6395.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Drug Concentration (Cmax) and Concentration at Trough (Ctrough) of GSK2269557</title>
        <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.</description>
        <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Drug Concentration (Cmax) and Concentration at Trough (Ctrough) of GSK2269557</title>
          <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis.</description>
          <population>PK Population.</population>
          <units>Picograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2175.5" spread="843.68"/>
                    <measurement group_id="O2" value="1871.8" spread="985.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" spread="48.71"/>
                    <measurement group_id="O2" value="248.9" spread="71.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Plasma Drug Concentration (Tmax) and Terminal Half-life (t1/2)</title>
        <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
        <time_frame>Day 1: Pre-dose, 5 minutes post dose, 30 minutes post-dose, 2 hours post-dose, 6 hours post-dose, 12 hours post-dose; Day 2: 24 hours post-dose; Day 3: 48 hours post-dose and Day 6: 120 hours post-dose</time_frame>
        <population>PK Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Drug Concentration (Tmax) and Terminal Half-life (t1/2)</title>
          <description>Blood samples were collected to evaluate the PK of GSK2269557 at the indicated time points. The PK parameters were calculated by standard non-compartmental analysis. Only those participants with data available at the specified time points were analyzed represented by n=X in the category titles.</description>
          <population>PK Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax, n=6,6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.08" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.07" upper_limit="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>t1/2, n=4,5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7" lower_limit="42" upper_limit="48"/>
                    <measurement group_id="O2" value="38.2" lower_limit="31" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Vital Signs of Potential Clinical Importance</title>
        <description>Vital signs included blood pressure (systolic and diastolic blood pressure) and heart rate measurements and were assessed with the participant in a semi-supine position after 5 minutes rest. The potential clinical concern range values for vital signs were: systolic blood pressure (lower &lt;85 millimeters of mercury and higher &gt;160 millimeters of mercury), diastolic blood pressure (lower &lt;45 millimeters of mercury and higher &gt;100 millimeters of mercury) and heart rate (lower &lt;40 beats per minute and higher &gt;110 beats per minute). Number of participants with vital signs of potential clinical importance are presented. Safety Population comprised of all randomized participants who received at least one dose of study treatment.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Signs of Potential Clinical Importance</title>
          <description>Vital signs included blood pressure (systolic and diastolic blood pressure) and heart rate measurements and were assessed with the participant in a semi-supine position after 5 minutes rest. The potential clinical concern range values for vital signs were: systolic blood pressure (lower &lt;85 millimeters of mercury and higher &gt;160 millimeters of mercury), diastolic blood pressure (lower &lt;45 millimeters of mercury and higher &gt;100 millimeters of mercury) and heart rate (lower &lt;40 beats per minute and higher &gt;110 beats per minute). Number of participants with vital signs of potential clinical importance are presented. Safety Population comprised of all randomized participants who received at least one dose of study treatment.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance</title>
        <description>Twelve-lead ECG was obtained using an ECG machine which automatically measured PR, QRS, QT and corrected QT (QTc) intervals. ECG parameters and their potential clinical importance range values were: absolute QTc interval (lower &gt;450 milliseconds [msec]), absolute PR interval (lower &lt;110 msec and upper &gt;220 msec), absolute QRS interval (lower &lt;75 msec and upper &gt;110 msec). Number of participants with electrocardiogram (ECG) values of potential clinical importance are presented.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance</title>
          <description>Twelve-lead ECG was obtained using an ECG machine which automatically measured PR, QRS, QT and corrected QT (QTc) intervals. ECG parameters and their potential clinical importance range values were: absolute QTc interval (lower &gt;450 milliseconds [msec]), absolute PR interval (lower &lt;110 msec and upper &gt;220 msec), absolute QRS interval (lower &lt;75 msec and upper &gt;110 msec). Number of participants with electrocardiogram (ECG) values of potential clinical importance are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>The maximal amount of air forcefully exhaled in 1 second (FEV1) and forced vital capacity (FVC) was measured using a spirometer. Baseline was latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline values from post-dose visit values. Mean change from Baseline in FVC and FEV1 is presented.</description>
        <time_frame>Baseline and Day 1</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) and Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>The maximal amount of air forcefully exhaled in 1 second (FEV1) and forced vital capacity (FVC) was measured using a spirometer. Baseline was latest pre-dose assessment. Change from Baseline was calculated by subtracting Baseline values from post-dose visit values. Mean change from Baseline in FVC and FEV1 is presented.</description>
          <population>Safety Population.</population>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="0.0554"/>
                    <measurement group_id="O2" value="-0.040" spread="0.2060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FVC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.177" spread="0.0836"/>
                    <measurement group_id="O2" value="0.065" spread="0.2780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Abnormalities of Potential Clinical Importance</title>
        <description>Hematology parameters and their potential clinical concern values were: Hematocrit (high flag: &gt;0.54 and change from Baseline: decrease of 0.075), hemoglobin (high flag: &gt;180 grams per Liter and change from Baseline: decrease of 25 grams per Liter), lymphocytes (low flag: &lt;0.8*10^9 cells per Liter), neutrophil count (low flag: &lt;1.5*10^9 cells per Liter), platelet count (low flag: &lt;100*10^9 cells per Liter and high flag: &gt;550*10^9 cells per Liter) and white blood cell count (low flag: &lt;3*10^9 cells per Liter and high flag: &gt;20*10^9 cells per Liter). Number of participants with hematology abnormalities of potential clinical importance are presented.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Abnormalities of Potential Clinical Importance</title>
          <description>Hematology parameters and their potential clinical concern values were: Hematocrit (high flag: &gt;0.54 and change from Baseline: decrease of 0.075), hemoglobin (high flag: &gt;180 grams per Liter and change from Baseline: decrease of 25 grams per Liter), lymphocytes (low flag: &lt;0.8*10^9 cells per Liter), neutrophil count (low flag: &lt;1.5*10^9 cells per Liter), platelet count (low flag: &lt;100*10^9 cells per Liter and high flag: &gt;550*10^9 cells per Liter) and white blood cell count (low flag: &lt;3*10^9 cells per Liter and high flag: &gt;20*10^9 cells per Liter). Number of participants with hematology abnormalities of potential clinical importance are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</title>
        <description>Clinical chemistry parameters and their potential clinical concern range values were: calcium (low flag &lt;2 millimoles/Liter [mmol/L] and high flag &gt;2.75 mmol/L), creatinine (high flag &gt;44.2 micromoles/Liter increase in change from Baseline), glucose (fasting) (&lt;3 mmol/L and &gt;9 mmol/L), potassium (low flag &lt;3 mmol/L and high flag &gt;5.5 mmol/L above ULN), sodium (low flag &lt;130 mmol/L and high flag &gt;150 mmol/L). Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Abnormalities of Potential Clinical Importance</title>
          <description>Clinical chemistry parameters and their potential clinical concern range values were: calcium (low flag &lt;2 millimoles/Liter [mmol/L] and high flag &gt;2.75 mmol/L), creatinine (high flag &gt;44.2 micromoles/Liter increase in change from Baseline), glucose (fasting) (&lt;3 mmol/L and &gt;9 mmol/L), potassium (low flag &lt;3 mmol/L and high flag &gt;5.5 mmol/L above ULN), sodium (low flag &lt;130 mmol/L and high flag &gt;150 mmol/L). Number of participants with clinical chemistry abnormalities of potential clinical importance are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
        <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
        <time_frame>Up to 12 days post-dose</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2269557 500 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>GSK2269557 750 mcg</title>
            <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)</title>
          <description>AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 days post-dose</time_frame>
      <desc>AE and SAE were collected for the Safety Population which comprised of all randomized participants who received at least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2269557 500 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 500 mcg via the ELLIPTA DPI on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>GSK2269557 750 mcg</title>
          <description>Eligible participants received a single dose of GSK2269557 750 mcg via the ELLIPTA DPI on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

